Kenvue Inc. Common Stock vs QXO Inc. Common Stock — how do they compare? Kenvue Inc. Common Stock trades at $18.12 (market cap $34.11B), while QXO Inc. Common Stock trades at $10.35 (market cap $11.43B). The key difference: Kenvue Inc. Common Stock is far larger — about 3× QXO Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.73% dividend while QXO Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kenvue Inc. Common Stock for 1 Days and QXO Inc. Common Stock for 0 Days on average.
| KVUE | QXO | |
|---|---|---|
Market Cap | $34.11B | $11.43B |
Volume | 27,388,811 | 21,645,941 |
Sector | Consumer Staples | Industrials |
52-Week High | $19.83 | $27.07 |
52-Week Low | $14.11 | $10.33 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $41.62B | $16.75B |
Dividend Yield | 4.73% | — |
Signals from Pluang's Aura AI — not financial advice
Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.
The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →